Pharmacodynamics of Cyclin D1 Degradation in Ovarian Cancer Xenografts with Repeated Oral SHetA2 Dosing.

导出 OA

翻译打印收藏纠错

作者： Ankur,Sharma ^[1] ; Xin,Liu ^[2] ; Vishal,Chandra ^[3] ; Rajani,Rai ^[3] ; Doris M,Benbrook ^[3] ; Sukyung,Woo ^[4]

作者单位： Department of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, 1110 N. Stonewall Ave., Oklahoma City, Oklahoma, 73117-1200, USA. ^[1] Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, 352 Pharmacy Building, Buffalo, New York, 14214, USA. ^[2] Department of Obstetrics and Gynecology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 975 NE 10th St, BRC 1217A, Oklahoma City, Oklahoma, 73104, USA. ^[3] Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, 352 Pharmacy Building, Buffalo, New York, 14214, USA. skwoo@buffalo.edu. ^[4]

关键词 SHetA2 anticancer drug cyclin D1 ovarian cancer

主题词人类(Humans);小鼠(Mice);动物(Animals);女(雌)性(Female);细胞周期蛋白D1(Cyclin D1);色满类(Chromans);卵巢肿瘤(Ovarian Neoplasms)

DOI 10.1208/s12248-023-00874-7

PMID 38087107

发布时间 2024-12-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交